Article

Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants

2023-03-27

Abstract excerpt

The ongoing emergence of SARS-CoV-2 Omicron subvariants and their rapid worldwide spread pose a threat to public health. From November 2022 to February 2023, newly emerged Omicron subvariants, including BQ.1.1, BF.7, BA.5.2, XBB.1, XBB.1.5, and BN.1.9, became prevalent global strains (>5% global prevalence). These Omicron subvariants are resistant to several therapeutic antibodies. Thus, the antiviral activities o...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: efa8becd-6ec1-548c-96c9-0af8b4845d8e
DOI: 10.1101/2023.03.26.533897

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariantsDOI 10.1101/2023.03.26.533897Read

Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025.Semantic proximity Read

Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants.Semantic proximity Read

Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variantsSemantic proximity Read

A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variantsSemantic proximity Read

A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies.Semantic proximity Read

Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and preventionSemantic proximity Read

Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent <i>in vitro</i> activity against the SARS-CoV-2 Omicron variantSemantic proximity Read

Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of ConcernSemantic proximity Read

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2Semantic proximity Read

Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron VariantsSemantic proximity Read

Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics.Semantic proximity Read

Omicron Subvariants: Clinical, Laboratory, and Cell Culture CharacterizationSemantic proximity Read